https://scholars.lib.ntu.edu.tw/handle/123456789/641492
標題: | Evolution and contemporary role of metronomic chemotherapy in the treatment of neuroblastoma | 作者: | SHU-WEI CHOU HSIU-HAO CHANG |
關鍵字: | Clinical trials; Metronomic chemotherapy; Neuroblastoma; Pediatrics | 公開日期: | 2-二月-2024 | 卷: | 588 | 來源出版物: | Cancer letters | 摘要: | Metronomic chemotherapy refers to the consistent and regular administration of low-dose chemotherapeutic agents over an extended period, with minimal or no extended drug-free intervals. The effectiveness of metronomic chemotherapy is derived from its capacity to impede tumor angiogenesis and foster antitumor immune responses, rather than merely interrupting tumor cell mitosis. Metronomic chemotherapy has been applied in the treatment of neuroblastoma for decades, including patients with newly diagnosed high-risk neuroblastoma and relapsed or refractory neuroblastoma. In the modern era of neuroblastoma treatment, metronomic chemotherapy remains a viable option for maintenance therapy in newly diagnosed neuroblastoma patients without access to autologous stem cell transplantation or immunotherapy, especially in resource-limited regions. For relapsed or refractory patients, metronomic chemotherapy is a suitable alternative for individuals intolerant to intensified treatments or receiving palliative care. Cyclophosphamide, etoposide, vinca alkaloids, and celecoxib constitute the primary components of current metronomic chemotherapy. Given the need for additional research to determine the optimal regimen, comprehensive studies must be conducted to explore and establish standardized metronomic chemotherapy protocols. Additionally, investigating potential biomarkers and clinical prognostic factors is imperative for future advancements in this field. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/641492 | ISSN: | 03043835 | DOI: | 10.1016/j.canlet.2024.216617 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。